Vincent Mccarthy the SVP – Dev & Strategy of Verisk Analytics, Inc. (VRSK) Unloaded 3,090 Shares; Prothena PLC (PRTA) Has 0.89 Sentiment

Verisk Analytics, Inc. (NASDAQ:VRSK) Logo

Prothena Corp PLC (PRTA) investors sentiment decreased to 0.89 in 2018 Q1. It’s down -0.29, from 1.18 in 2017Q4. The ratio has dropped, as 58 institutional investors started new or increased positions, while 65 reduced and sold stakes in Prothena Corp PLC. The institutional investors in our database now possess: 29.85 million shares, down from 31.32 million shares in 2017Q4. Also, the number of institutional investors holding Prothena Corp PLC in top ten positions was flat from 0 to 0 for the same number . Sold All: 30 Reduced: 35 Increased: 36 New Position: 22.

The well informed man Vincent Mccarthy who is SVP – Corp Dev & Strategy of Verisk Analytics Inc sold some 3,090 shares of the stock exchange listed company worth approx. $337,181 U.S. Dollars which is based on a market stock price of $109.1 for a share. In the last 30 days, he also sold 35,000 shares with a total value $3,817,100 USD. This trade was made on June 18, 2018. A document filed with the D.C. based-SEC and freely available here, reveals more info for the trade. The probability of this deal remaining ignored is nil due to its volume, with the SVP – Corp Dev & Strategy now holding 34,037 shares – that is 0.02% of the total market cap of the Company.

Analysts await Verisk Analytics, Inc. (NASDAQ:VRSK) to report earnings on August, 7. They expect $1.00 EPS, up 21.95% or $0.18 from last year’s $0.82 per share. VRSK’s profit will be $165.26M for 27.40 P/E if the $1.00 EPS becomes a reality. After $0.94 actual EPS reported by Verisk Analytics, Inc. for the previous quarter, Wall Street now forecasts 6.38% EPS growth.

Verisk Analytics, Inc. provides data analytics solutions for clients in the insurance, natural resources, healthcare, financial services, and risk management markets in the United States and internationally. The company has market cap of $18.11 billion. The companyÂ’s Risk Assessment segment offers solutions to property and casualty insurance clients and focuses on prediction of loss, and selection and pricing of risk. It has a 31.84 P/E ratio. The Company’s solutions include industry-standard insurance programs that help P&C insurers in defining coverage and issue policies; actuarial services to help its clients analyze and price their risks; and customized services that include assisting with the development of independent insurance programs, analysis of their own underwriting experience, development of classification systems and rating plans, and other business decisions, as well as supplies information to various clients in other markets.

Since December 20, 2017, it had 5 insider purchases, and 17 selling transactions for $53.13 million activity. Shavel Lee also bought $37,838 worth of Verisk Analytics, Inc. (NASDAQ:VRSK) shares. Thompson Kenneth E had sold 60,569 shares worth $6.37 million on Friday, March 16. 73,587 Verisk Analytics, Inc. (NASDAQ:VRSK) shares with value of $7.37M were sold by BROWN HYATT J. McCarthy Vincent de P. sold $834,000 worth of Verisk Analytics, Inc. (NASDAQ:VRSK) on Thursday, March 15. Another trade for 8,500 shares valued at $888,250 was made by Foskett Christopher M on Wednesday, March 14. Another trade for 64,063 shares valued at $6.72 million was made by Stephenson Scott G on Tuesday, May 15. 3,000 shares valued at $300,000 were sold by MILLS ANDREW G on Wednesday, February 21.

Among 20 analysts covering Verisk Analytics (NASDAQ:VRSK), 10 have Buy rating, 1 Sell and 9 Hold. Therefore 50% are positive. Verisk Analytics has $118.0 highest and $70 lowest target. $98.75’s average target is -9.90% below currents $109.6 stock price. Verisk Analytics had 51 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Keefe Bruyette & Woods given on Monday, August 21. The rating was maintained by Barclays Capital on Thursday, November 2 with “Overweight”. The firm earned “Hold” rating on Wednesday, April 18 by BMO Capital Markets. BMO Capital Markets maintained the stock with “Market Perform” rating in Thursday, May 3 report. Credit Suisse maintained Verisk Analytics, Inc. (NASDAQ:VRSK) on Thursday, November 2 with “Neutral” rating. Sterne Agee CRT initiated Verisk Analytics, Inc. (NASDAQ:VRSK) on Tuesday, March 22 with “Neutral” rating. The stock of Verisk Analytics, Inc. (NASDAQ:VRSK) earned “Buy” rating by Keefe Bruyette & Woods on Friday, December 1. The rating was maintained by JP Morgan on Thursday, February 15 with “Neutral”. The rating was reinitiated by Bruyette & Woods” on Tuesday, July 21 with “Outperform”. The firm has “Hold” rating given on Tuesday, July 11 by BMO Capital Markets.

The stock decreased 0.27% or $0.3 during the last trading session, reaching $109.6. About 469,254 shares traded. Verisk Analytics, Inc. (NASDAQ:VRSK) has risen 30.70% since June 19, 2017 and is uptrending. It has outperformed by 18.13% the S&P500. Some Historical VRSK News: ; 06/03/2018 Verisk Projects Written Premium for Commercial Cyber Liability to Reach $6.2B by 2020; 01/05/2018 – VERISK ANALYTICS 1Q ADJ. EPS 94C, EST. 94C; 07/03/2018 – Cal EMA Spills: SPILL Report – Verisk 3E Carlsbad – 03/07/2018 01:53 PM; 17/05/2018 – EXCLUSIVE-As Rosneft’s Vietnam unit drills in disputed area of South China Sea, Beijing issues warning; 09/04/2018 – AIR Worldwide Collaborates with RenaissanceRe to Develop Industry’s First Probabilistic Model for Extreme Liability Events; 26/04/2018 – REG-Verisk Announces Operating Segment Change Effective for the Quarter Ended March 31, 2018; 24/05/2018 – Geomni Achieves Widespread Aerial lmagery Coverage of Parcels and Structures in the United States; 16/04/2018 – Verisk Analytics Group President Nana Banerjee to Resign; 17/04/2018 – Hyundai Motor Amer Selects Verisk for Usage-Based Insurance; 15/05/2018 – BERKSHIRE HATHAWAY – CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DEC 31, 2017

More important recent Verisk Analytics, Inc. (NASDAQ:VRSK) news were published by: which released: “Omnitracs to Join Verisk Data Exchange” on June 05, 2018, also published article titled: “Geomni Achieves Widespread Aerial Imagery Coverage of Parcels and Structures in the United States”, published: “ISO Launches New Insurance Program to Address the Rapidly Growing Home Healthcare Insurance Market” on May 31, 2018. More interesting news about Verisk Analytics, Inc. (NASDAQ:VRSK) was released by: and their article: “Argus Launches New Industry-Leading Regulatory and Compliance Solution on Cloud” with publication date: May 22, 2018.

Investors sentiment is 1.08 in Q1 2018. Its the same as in 2017Q4. It is flat, as 27 investors sold Verisk Analytics, Inc. shares while 158 reduced holdings. only 69 funds opened positions while 131 raised stakes. 145.38 million shares or 0.63% more from 144.47 million shares in 2017Q4 were reported. The Israel-based Psagot Invest House has invested 0.01% in Verisk Analytics, Inc. (NASDAQ:VRSK). Sawgrass Asset Mgmt Ltd Com owns 1.29% invested in Verisk Analytics, Inc. (NASDAQ:VRSK) for 258,693 shares. 5,862 were accumulated by Cubist Systematic Strategies Ltd Liability. First Manhattan reported 0% stake. Bell Bancshares reported 5,325 shares stake. Bb&T Secs Limited Liability Corp holds 0.1% in Verisk Analytics, Inc. (NASDAQ:VRSK) or 83,647 shares. Kcm Inv Advsr Ltd Limited Liability Company stated it has 7,690 shares. Ontario Teachers Pension Plan Board, Ontario – Canada-based fund reported 4,258 shares. New Mexico Educational Retirement Board has invested 0.06% in Verisk Analytics, Inc. (NASDAQ:VRSK). Nuwave Inv Management Ltd Llc holds 0.04% or 225 shares in its portfolio. Avalon Advsrs Limited Liability Com reported 0.05% of its portfolio in Verisk Analytics, Inc. (NASDAQ:VRSK). Dupont Capital Mngmt holds 0% or 1,557 shares in its portfolio. Earnest Ptnrs Lc accumulated 62 shares. State Common Retirement Fund stated it has 480,825 shares or 0.06% of all its holdings. Quantitative Systematic Strategies Limited Com owns 2,098 shares for 0.05% of their portfolio.

Rock Springs Capital Management Lp holds 0.5% of its portfolio in Prothena Corporation plc for 318,500 shares. Bb Biotech Ag owns 400,000 shares or 0.41% of their US portfolio. Moreover, Oak Ridge Investments Llc has 0.29% invested in the company for 142,351 shares. The New York-based Pinnacle Associates Ltd has invested 0.23% in the stock. Clearbridge Llc, a Maryland-based fund reported 273,420 shares.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The company has market cap of $579.81 million. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. It currently has negative earnings. The firm has a license, development, and commercialization agreement with F.

The stock decreased 1.95% or $0.29 during the last trading session, reaching $14.56. About 376,814 shares traded. Prothena Corporation plc (PRTA) has declined 73.35% since June 19, 2017 and is downtrending. It has underperformed by 85.92% the S&P500. Some Historical PRTA News: ; 20/03/2018 – Prothena, Celgene Collaboration Focuses on Preclinical Programs Targeting Proteins Implicated in Neurodegenerative Diseases; 24/05/2018 – Prothena Expects Its 2018 Net Cash Burn From Operating and Investing Activities to Be $40M-$50M; 08/05/2018 – Prothena 1Q Loss $48.7M; 23/04/2018 – RT @JChatterleyBBG: Credit to @muddywatersre on this one, @BloombergTV I/v from 2017 – Carson Block questioning $PRTA value; 23/04/2018 – FT Alphaville – Blog: Prothena goes splat; 23/04/2018 – With Woodford & $PRTA behind us, tomorrow we’ll debunk another supposedly legendary money manager who has bought up 25%+ of a lousy company and made it his biggest position. He’s less into bad drugs, more into bad land; 12/03/2018 – Prothena to Present a Broad Range of Scientific and Health Outcomes Data at the 16th International Symposium on Amyloidosis; 20/03/2018 – PROTHENA CORPORATION PLC PRTA.O : RBC RAISES TARGET PRICE TO $86 FROM $83; 23/04/2018 – $PRTA fails NEOD001 trial, shares -60%. Our original report at; 23/04/2018 – FT Alphaville – Blog: Prothena goes splat [Update]

Ratings analysis reveals 100% of Prothena’s analysts are positive. Out of 3 Wall Street analysts rating Prothena, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $69.0 while the high is $86.0. The stock’s average target of $76.67 is 426.58% above today’s ($14.56) share price. PRTA was included in 3 notes of analysts from December 21, 2016. The stock of Prothena Corporation plc (NASDAQ:PRTA) has “Overweight” rating given on Wednesday, April 12 by Cantor Fitzgerald. Piper Jaffray initiated Prothena Corporation plc (NASDAQ:PRTA) rating on Wednesday, April 12. Piper Jaffray has “Overweight” rating and $69.0 target. SunTrust initiated the shares of PRTA in report on Wednesday, December 21 with “Buy” rating.

Analysts await Prothena Corporation plc (NASDAQ:PRTA) to report earnings on August, 14. They expect $-0.92 EPS, down 100.00% or $0.46 from last year’s $-0.46 per share. After $-1.26 actual EPS reported by Prothena Corporation plc for the previous quarter, Wall Street now forecasts -26.98% EPS growth.

Verisk Analytics, Inc. (NASDAQ:VRSK) Institutional Positions Chart